CD19 drugs for Follicular Lymphoma
2 tracked CD19 drugs in the Follicular Lymphoma race. The class explanation lives on the CD19 page; the full indication pipeline across every mechanism is on the Follicular Lymphoma page.
1 approved / phase 41 Phase 1/2
Head-to-head evidence: Tafasitamab vs Zugocabtagene geleucel